$750 Million is the total value of Bellevue Group AG's 132 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALGN | New | ALIGN TECHNOLOGY INC | $15,624,000 | – | 136,200 | +100.0% | 2.08% | – |
| WBA | New | WALGREENS BOOTS ALLIANCE INC | $13,322,000 | – | 160,409 | +100.0% | 1.78% | – |
| ABC | New | AMERISOURCEBERGEN CORP | $9,036,000 | – | 102,099 | +100.0% | 1.20% | – |
| HRC | New | HILL-ROM HOLDINGS INC | $7,221,000 | – | 102,274 | +100.0% | 0.96% | – |
| THC | New | TENET HEALTHCARE CORP | $5,766,000 | – | 325,546 | +100.0% | 0.77% | – |
| GNMK | New | GENMARK DIAGNOSTICS INC. | $4,008,000 | – | 312,666 | +100.0% | 0.53% | – |
| LIVN | New | LIVANOVA PLC | $3,146,000 | – | 64,189 | +100.0% | 0.42% | – |
| XRAY | New | DENTSPLY SIRONA INC | $2,810,000 | – | 45,000 | +100.0% | 0.37% | – |
| TSRO | New | TESARO INC | $2,462,000 | – | 16,000 | +100.0% | 0.33% | – |
| BIVV | New | BIOVERATIV INC | $1,239,000 | – | 22,750 | +100.0% | 0.16% | – |
| MDCO | New | MEDICINES CO | $1,051,000 | – | 21,500 | +100.0% | 0.14% | – |
| IART | New | INTEGRA LIFESCIENCES HLDGS C | $632,000 | – | 15,000 | +100.0% | 0.08% | – |
| CEMP | New | CEMPRA INC | $619,000 | – | 165,000 | +100.0% | 0.08% | – |
| TDOC | New | TELADOC INC | $500,000 | – | 20,000 | +100.0% | 0.07% | – |
| CERS | New | CERUS CORP | $134,000 | – | 30,000 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bellevue Asset Management AG #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IONIS PHARMACEUTICALS INC | 31 | Q3 2023 | 9.3% |
| Vertex Pharmaceuticals Incorporated | 31 | Q3 2023 | 5.9% |
| NEUROCRINE BIOSCIENCES INC | 31 | Q3 2023 | 5.7% |
| Incyte Corporation | 31 | Q3 2023 | 5.4% |
| INTUITIVE SURGICAL INC | 31 | Q3 2023 | 4.7% |
| ABBOTT LABS | 31 | Q3 2023 | 4.6% |
| ELEVANCE HEALTH INC | 31 | Q3 2023 | 4.3% |
| UnitedHealth Group Incorporated | 31 | Q3 2023 | 3.6% |
| ALNYLAM PHARMACEUTICALS INC | 31 | Q3 2023 | 3.7% |
| Boston Scientific Corporation | 31 | Q3 2023 | 2.5% |
View Bellevue Group AG's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-02-14 |
| SC 13G | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View Bellevue Group AG's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.